Healthlead operates as a holding company through subsidiaries by investing in drugstores and a health product distributor who collaborates with research institutions to develop and distribute innovative health products.
| 3M24 | 3M23 | 2023 | 2022 |
|---|
| Revenues | 494.82 | 388.34 | 1,659.31 | 1,538.21 |
| Expenses | 470.79 | 370.56 | 1,558.59 | 1,389.82 |
| Net Profit (Loss) | 18.58 | 12.80 | 74.68 | 118.23 |
| Assets | 1,432.08 | 1,311.03 | 1,382.35 | 1,288.19 |
| Liabilities | 445.45 | 356.25 | 414.29 | 346.20 |
| Shareholders' Equity | 986.63 | 954.78 | 968.05 | 941.99 |
| Operating | 32.86 | 12.50 | 91.26 | 136.20 |
| Investing | 22.13 | -67.78 | 177.28 | -624.51 |
| Financing | -9.33 | -7.36 | -80.08 | -70.34 |
| EPS (Baht) | 0.07 | 0.05 | 0.27 | 0.43 |
| GP Margin (%) | 21.73 | 21.47 | 23.06 | 24.76 |
| NP Margin (%) | 3.75 | 3.29 | 4.50 | 7.69 |
| D/E Ratio (x) | 0.45 | 0.37 | 0.43 | 0.37 |
| ROE (%) | 8.29 | 10.90 | 7.82 | 13.08 |
| ROA (%) | 7.76 | 10.30 | 7.50 | 12.33 |
The Group aims to expand its branch continuously, targeting Bangkok and metropolitan areas due to the high market value. The target is to open 20 new branches in 2024. In addition, the Group also plans to launch innovative products under its own brands and expand its distribution channels.
- Aim to operate with fairness, legitimacy, and transparency.
- Strictly comply with the law and regulations.
- Operate in consistent with labor law and concerns regarding human rights.
- Show responsibility to customers by providing high quality products and customer services, with accurate and updated information, and keeping client confidentiality.
- Implement a green campaign by reducing usage of plastic bags and paper boxes. Implementing ERP systems to reduce paper usage. The Group initiated a pioneering project, by applying e-tax to business partners, in order to reduce paper use, for partners who are ready for the transformation.
- Place its importance on a healthy community and support sustainable development. The Group has participated in diverse activities in various aspects such as public health, education, and religion.
Investing in drugstores and a health product distributor who engages in with outsourced research teams to co-develop the most innovative health products. The Group owns four brands of drugstores and operates 52 branches throughout Bangkok and Metropolitan area as of 31 March 2024. It also owns two brands: ‘PRIME’ - products in dietary supplements; ‘BESUTO’ - innovative hygiene and health products; and holds exclusivity of brand ‘BOMSKIN’ cosmeceutical skin care made in Korea.
In Q1-2024 revenues from sales were 482.41 MB, 25.17% YOY increase - 99.01% of revenues from sales came from retail sales. Revenue from sales of all four categories increase both YOY and QOQ. The highest growth was from medical food, grew 36.20% YOY, followed by personal healthcare 31.79% YOY.
Other income jumped 102.80% YOY from the rapid increase in the number of branches and selling area resulted in increased revenue from existing and additional services. Icare Health Co., Ltd. (its subsidiary) had 6.45 MB net gain on disposal of non-current assets classified as held-for-sales in Q1-2024. The assets included land and buildings previously used as Icare Health's warehouse. Icare Health sold and transferred the property on February 8, 2024. The Group reported 18.58 MB net profit, increased 45.17% YOY.
- As of 31 March 2024, the Group had a total of 52 branches, by adding two branches in Q1-2024 in Bangkok and Metropolitan area.
- Certified as Accredited Pharmacy by The Office of Community Pharmacy Accreditation (Thailand) to legitimately join the National Health Security System Program or the so-call "golden card" 30 Baht health care scheme.
- VAT REFUND FOR TOURISTS is available in all branches.
- Implemented e-Tax Invoice & e-Receipt and joined 'Easy e-Receipt program', the government's domestic consumption stimulus plan, from January 1, 2024 to February 15, 2024.
- Since founding the drugstore 30 years ago, the Group has sourced from two major distributors. The partnership has gone well. However, the Group has regularly reviewed new suppliers to ensure it secures sufficient products.
- In terms of competition risk, the Group focuses on expanding branches to strategic locations in Bangkok and having pharmacists stationed at all branches to guarantee superior quality of services.
- The Group is widely recognized in pharmacist professional group, as it has been offering internship programs for pharmaceutical students from leading universities for years. This has efficiently mitigated the risk of pharmacist shortage.
- Gold Medal for the invention Prime B0051 plus at the 2021 Japan Design, Idea & Invention Expo, August 18-20, 2021
- Silver Medal for the Invention Innovation Entitled: BESUTO-12 at the iCAN 2020 (Toronto, Canada), August 29, 2020
- Special Award in recognition of excellent invention/innovation of BESUTO-12 at the iCAN 2020 (Toronto, Canada), August 29, 2020
- Silver Medal for SPECIAL EDITION 2022 from Cell Matrix Technology Prime VISON Product - INVENTION GENEVA EVALUATION DAYS, March 28, 2022
- Gold Medal for the invention Prime MOVX2 -2022 Japan Design, Idea & Invention Expo, July 1-3, 2022
| as of 29/03/24 | HL | SERVICE | mai |
|---|---|---|---|
| P/E (X) | 43.71 | 111.30 | 109.40 |
| P/BV (X) | 3.37 | 2.64 | 2.11 |
| Dividend yield (%) | 1.25 | 1.89 | 1.80 |
| 29/03/24 | 28/12/23 | 30/12/22 | |
|---|---|---|---|
| Market Cap (MB) | 3,264.00 | 2,828.80 | 6,691.20 |
| Price (B/Share) | 12.00 | 10.40 | 24.60 |
| P/E (X) | 43.71 | 35.81 | 62.92 |
| P/BV (X) | 3.37 | 3.02 | 7.38 |
